Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma.
Crocchiolo R, Chabannon C, El-Cheikh J, Esterni B, Lemarié C, Fürst S, Castagna L, Bouabdallah R, Ladaique P, Coso D, Schiano JM, Stoppa AM, Rey J, Ivanov V, Aurran T, Faucher C, Blaise D, Calmels B. Crocchiolo R, et al. Among authors: aurran t. Leuk Lymphoma. 2013 Feb;54(2):417-20. doi: 10.3109/10428194.2012.702901. Epub 2012 Jul 9. Leuk Lymphoma. 2013. PMID: 22702654 No abstract available.
A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
Coso D, Sebban C, Boulat O, Biron P, Rey J, Aurran T, Chabannon C, Xerri L, Chetaille B, Esterni B, Ivanov V, Stoppa AM, Schiano de Collela JM, Gastaut JA, Maraninchi D, Bouabdallah R. Coso D, et al. Among authors: aurran t. Bone Marrow Transplant. 2006 Aug;38(3):217-22. doi: 10.1038/sj.bmt.1705414. Epub 2006 Jun 12. Bone Marrow Transplant. 2006. PMID: 16770316 Clinical Trial.
Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity.
Garciaz S, Coso D, Schiano de Collela JM, Broussais F, Stoppa AM, Aurran T, Chabannon C, Helvig A, Xerri L, Blaise D, Bouabdallah R. Garciaz S, et al. Among authors: aurran t. Bone Marrow Transplant. 2016 Feb;51(2):319-21. doi: 10.1038/bmt.2015.257. Epub 2015 Nov 2. Bone Marrow Transplant. 2016. PMID: 26524266 No abstract available.
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.
Leblond V, Morel P, Dilhuidy MS, Leleu X, Soussain C, Leprête S, Dreyfus B, Dartigeas C, Mahé B, Anglaret B, Pégourié B, Besson C, Aurran T, Vekhoff A, Tournilhac O, Banos A, Oya H, Lejeune J, Ouzegdouh M, Chevret S; French Innovative Leukemia Organization (FILO). Leblond V, et al. Among authors: aurran t. Leuk Lymphoma. 2017 Nov;58(11):2615-2623. doi: 10.1080/10428194.2017.1307357. Epub 2017 Apr 10. Leuk Lymphoma. 2017. PMID: 28395585 Clinical Trial.
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Michallet AS, Letestu R, Le Garff-Tavernier M, Aanei C, Ticchioni M, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, Salles G, Tournilhac O, Delmer A, Portois C, Pegourie B, Leblond V, Tomowiak C, De Guibert S, Orsini Piocelle F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan-Graczyk M, Vilque JP, Aurran T, Cymbalista F, Lepretre S, Levy V, Nguyen-Khac F, Feugier P. Michallet AS, et al. Among authors: aurran t. Blood. 2021 Feb 25;137(8):1019-1023. doi: 10.1182/blood.2020008164. Blood. 2021. PMID: 33167024 Free article. Clinical Trial.
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Cymbalista F, Ross-Weil D, Leprêtre S. Feugier P, et al. Among authors: aurran t. Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15. Haematologica. 2018. PMID: 29545348 Free PMC article. No abstract available.
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Michallet AS, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, Salles G, Tournilhac O, Delmer A, Portois C, Pegourie B, Leblond V, Tomowiak C, de Guibert S, Orsini F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan Graczyk M, Vilque JP, Aurran T, Cymbalista F, Lepretre S, Lévy V, Nguyen-Khac F, Le Garff-Tavernier M, Aanei C, Ticchioni M, Letestu R, Feugier P. Michallet AS, et al. Among authors: aurran t. Lancet Haematol. 2019 Sep;6(9):e470-e479. doi: 10.1016/S2352-3026(19)30113-9. Epub 2019 Jul 16. Lancet Haematol. 2019. PMID: 31324600 Clinical Trial.
First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.
Meunier G, Ysebaert L, Nguyen-Thi PL, Lepretre S, Quinquenel A, Dupuis J, Lemal R, Aurran T, Tomowiak C, Cymbalista F, Dilhuydy MS, Brion A, Morel P, Cazin B, Leblond V, Cartron G, Ré D, Béné MC, Michallet AS, Feugier P. Meunier G, et al. Among authors: aurran t. Hematol Oncol. 2017 Dec;35(4):671-678. doi: 10.1002/hon.2370. Epub 2016 Nov 22. Hematol Oncol. 2017. PMID: 27878835
23 results